HC Wainwright Cuts Earnings Estimates for Vera Therapeutics

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Research analysts at HC Wainwright dropped their Q2 2025 EPS estimates for Vera Therapeutics in a research note issued to investors on Wednesday, May 7th. HC Wainwright analyst A. He now anticipates that the company will post earnings of ($0.90) per share for the quarter, down from their prior forecast of ($0.81). HC Wainwright currently has a "Buy" rating and a $75.00 price target on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics' Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.84) EPS, FY2025 earnings at ($3.42) EPS, Q1 2026 earnings at ($0.78) EPS, Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($2.51) EPS.

A number of other brokerages also recently weighed in on VERA. The Goldman Sachs Group began coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price target for the company. Wolfe Research began coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price target for the company. JPMorgan Chase & Co. cut their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a report on Tuesday, March 4th. Cantor Fitzgerald cut their price target on shares of Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a report on Wednesday. Finally, Guggenheim upped their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $63.33.

Vera Therapeutics Stock Performance

Shares of NASDAQ VERA traded down $0.26 during midday trading on Friday, reaching $21.77. 1,262,456 shares of the company traded hands, compared to its average volume of 778,875. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The stock has a 50-day moving average price of $24.22 and a 200 day moving average price of $34.65. Vera Therapeutics has a 52 week low of $18.53 and a 52 week high of $51.61. The company has a market cap of $1.39 billion, a price-to-earnings ratio of -8.34 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same quarter last year, the company posted ($0.56) EPS.

Institutional Trading of Vera Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Huntington National Bank purchased a new stake in Vera Therapeutics during the fourth quarter valued at about $26,000. Summit Investment Advisors Inc. lifted its position in shares of Vera Therapeutics by 16.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after purchasing an additional 639 shares in the last quarter. AlphaQuest LLC purchased a new stake in shares of Vera Therapeutics in the fourth quarter worth approximately $34,000. Alliancebernstein L.P. lifted its position in shares of Vera Therapeutics by 2.0% in the fourth quarter. Alliancebernstein L.P. now owns 40,350 shares of the company's stock worth $1,706,000 after purchasing an additional 800 shares in the last quarter. Finally, E Fund Management Co. Ltd. lifted its position in shares of Vera Therapeutics by 22.3% in the fourth quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company's stock worth $262,000 after purchasing an additional 1,130 shares in the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.